肺癌靶向治疗的更为高效的药物出现了。诺华研发的Ceritinib是一种ALK (anaplastic lymphoma kinase) 抑制剂,体外试验显示,其ALK抑制效能高出克里唑蒂尼(crizotinib)20倍。今天出版的新英格兰医学杂志 (NEJM) 发表了Ceritinib 的临床1期研究结果:对克里唑蒂尼耐药的ALK-重排NSCLC患者,服用Ceritinib后所产生的治疗应答率高达56%。
论文链接: A More Potent ALK Inhibitor in Lung Cancer
March 27, 2014 | A.T. Shaw and Others
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in 56% of those who had resistance to crizotinib.
肺癌分类图
新药的四期临床试验(从下往上看~.~)